H. Tatum

Medicine · Health Sciences

12h-index957citations14works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(12), Hepatitis B Virus Studies(6), Liver Disease Diagnosis and Treatment(6), HIV/AIDS drug development and treatment(4), Immunodeficiency and Autoimmune Disorders(3)

Publications14 total

Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis
Journal of Hepatology·2020· 58 cited
No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease
Gastroenterology·2016· 131 citedOpen Access
A randomized, placebo‐controlled study of the <scp>NS</scp>5B inhibitor beclabuvir with peginterferon/ribavirin for <scp>HCV</scp> genotype 1
Journal of Viral Hepatitis·2014· 17 citedOpen Access
Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
Gastroenterology·2014· 59 citedOpen Access
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study
Gut·2014· 118 cited
Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
Gastroenterology·2013· 198 citedOpen Access
1418 DACLATASVIR COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION: COMMAND GT2/3 STUDY
Journal of Hepatology·2013· 34 citedOpen Access
1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
Journal of Hepatology·2013· 37 citedOpen Access
1424 SYNERGISTIC INTERACTIONS OF HCV NS5A REPLICATION COMPLEX INHIBITORS SENSITIZE RESISTANT VARIANTS AND ENHANCE THE EFFICACY OF DACLATASVIR (DCV, BMS-790052) IN VITRO AND IN VIVO
2013
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
The Lancet Infectious Diseases·2012· 147 cited
1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
Journal of Hepatology·2012· 5 cited
1373 FIRST REPORT OF SVR12 FOR A NS5A REPLICATION COMPLEX INHIBITOR BMS-790052 IN COMBINATION WITH PEG-IFNa-2A AND RBV: PHASE 2A TRIAL IN TREATMENT-NAIVE HCV-GENOTYPE-1 SUBJECTS
Journal of Hepatology·2011· 26 citedOpen Access
Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid
Journal of Virological Methods·2010· 112 cited
1189 ONCE-DAILY NS5A INHIBITOR (BMS-790052) PLUS PEGINTERFERON-ALPHA-2A AND RIBAVIRIN PRODUCES HIGH RATES OF EXTENDED RAPID VIROLOGIC RESPONSE IN TREATMENT-NAIVE HCV-GENOTYPE 1 SUBJECTS: PHASE 2A TRIAL
Journal of Hepatology·2010· 15 cited

Frequent Co-authors

Paul J. Thuluvath(9), Christophe Hézode(7), Vinod K. Rustgi(7), Fiona McPhee(7), Eric Hughes(7), Eric Lawitz(5), Stanislas Pol(5), Megan Wind‐Rotolo(5), Claudia Martorell(5), Gregory T. Everson(4), M. Rodríguez‐Torres(4), Marc Bourlière(4), Reem Ghalib(4), Elizabeth Cooney(4), Karen Sims(3), V. Loustaud‐Ratti(3), Howard Schwartz(3), Patrick Marcellin(3), Timothy Eley(3), C Pasquinelli(3)